PL2666476T3 - Dokomorowe dostarczanie enzymu dla lizosomalnych chorób spichrzeniowych - Google Patents

Dokomorowe dostarczanie enzymu dla lizosomalnych chorób spichrzeniowych

Info

Publication number
PL2666476T3
PL2666476T3 PL13173895T PL13173895T PL2666476T3 PL 2666476 T3 PL2666476 T3 PL 2666476T3 PL 13173895 T PL13173895 T PL 13173895T PL 13173895 T PL13173895 T PL 13173895T PL 2666476 T3 PL2666476 T3 PL 2666476T3
Authority
PL
Poland
Prior art keywords
lysosomal storage
storage diseases
enzyme delivery
intraventricular
intraventricular enzyme
Prior art date
Application number
PL13173895T
Other languages
English (en)
Inventor
James Dodge
Marco Passini
Lamya Shihabuddin
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2666476T3 publication Critical patent/PL2666476T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
PL13173895T 2006-01-20 2007-01-22 Dokomorowe dostarczanie enzymu dla lizosomalnych chorób spichrzeniowych PL2666476T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76037806P 2006-01-20 2006-01-20
PCT/US2007/001566 WO2007084737A2 (en) 2006-01-20 2007-01-22 Intraventricular enzyme delivery for lysosomal storage diseases
EP13173895.7A EP2666476B1 (en) 2006-01-20 2007-01-22 Intraventricular enzyme delivery for lysosomal storage diseases
EP07716858.1A EP1984018B1 (en) 2006-01-20 2007-01-22 Intraventricular enzyme delivery for lysosomal storage diseases

Publications (1)

Publication Number Publication Date
PL2666476T3 true PL2666476T3 (pl) 2019-06-28

Family

ID=38288294

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13173895T PL2666476T3 (pl) 2006-01-20 2007-01-22 Dokomorowe dostarczanie enzymu dla lizosomalnych chorób spichrzeniowych
PL07716858T PL1984018T3 (pl) 2006-01-20 2007-01-22 Dokomorowe dostarczanie enzymu w lizosomalnych chorobach spichrzeniowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07716858T PL1984018T3 (pl) 2006-01-20 2007-01-22 Dokomorowe dostarczanie enzymu w lizosomalnych chorobach spichrzeniowych

Country Status (19)

Country Link
US (4) US8926967B2 (pl)
EP (3) EP2666476B1 (pl)
JP (1) JP5681345B2 (pl)
CN (1) CN101431960A (pl)
AR (2) AR059089A1 (pl)
BR (1) BRPI0706699A2 (pl)
CA (2) CA2966155A1 (pl)
DK (2) DK2666476T3 (pl)
ES (2) ES2526710T3 (pl)
HU (1) HUE041840T2 (pl)
IL (2) IL192740A (pl)
LT (1) LT2666476T (pl)
MX (1) MX349749B (pl)
PL (2) PL2666476T3 (pl)
PT (2) PT1984018E (pl)
RU (3) RU2529830C2 (pl)
SI (2) SI2666476T1 (pl)
TR (1) TR201903855T4 (pl)
WO (1) WO2007084737A2 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
LT1988823T (lt) 2006-02-09 2018-12-10 Genzyme Corporation Lėtas intraventrikuliarinis pateikimas
CA2684946C (en) 2007-05-16 2015-03-31 The Brigham And Women's Hospital, Inc. Treatment of synucleinopathies
CN105879047A (zh) * 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
LT3421603T (lt) 2009-05-02 2022-01-10 Genzyme Corporation Genų terapija, skirta neurodegeneraciniams sutrikimams
IL300625A (en) * 2009-08-28 2023-04-01 Icahn School Med Mount Sinai Increasing dose replacement enzyme for the treatment of acid sphingomyelinase deficiency
SI3205351T1 (sl) 2010-04-23 2023-09-29 Alexion Pharmaceuticals, Inc., Encim za bolezen lizosomskega shranjevanja
ES2754234T3 (es) 2010-06-25 2020-04-16 Shire Human Genetic Therapies Métodos y composiciones para la administración SNC de iduronato-2-sulfatasa
DK2588130T3 (en) * 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
US20110318324A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Methods and compositions for cns delivery of b-galactocerebrosidase
RU2012154576A (ru) * 2010-06-25 2014-07-27 Шир Хьюман Дженетик Терапис, Инк. Способы и композиции для доставки к цнс гепаран-n-сульфатазы
LT2585104T (lt) * 2010-06-25 2019-10-25 Shire Human Genetic Therapies Būdai ir kompozicijos, skirti arilsulfatazės a pristatymui į cns
LT3626258T (lt) 2010-06-25 2021-12-10 Shire Human Genetic Therapies, Inc. Būdai ir kompozicijos, skirti iduronato-2-sulfatazės įvedimui į cns
JP2012062312A (ja) * 2010-08-19 2012-03-29 Yoshikatsu Eto ハンター症候群の治療剤
SG188456A1 (en) * 2010-09-09 2013-04-30 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
US9387236B2 (en) * 2011-06-10 2016-07-12 Prothera Inc. Pharmaceutical compositions containing protease and methods for the treatment of lysosomal storage diseases
WO2013096912A2 (en) * 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
WO2013096899A2 (en) 2011-12-23 2013-06-27 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
EA039246B1 (ru) * 2012-12-06 2021-12-22 Шир Хьюман Дженетик Терапис, Инк. Способ лечения когнитивных нарушений, связанных с синдромом хантера
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
SG10201709925SA (en) 2013-06-07 2017-12-28 Genzyme Corp Marker for acid sphingomyelinase disorders and uses thereof
JP6616189B2 (ja) 2013-12-25 2019-12-04 Ｊｃｒファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
WO2015119989A1 (en) * 2014-02-04 2015-08-13 New York University Progranulin (pgrn) and its derivatives for diagnosis and treatment of lysosomal storage diseases
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2016283343B2 (en) 2015-06-24 2022-05-19 Jcr Pharmaceuticals Co., Ltd. Anti-human transferrin receptor antibody permeating blood-brain barrier
CA2990565A1 (en) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf and anti-human transferrin receptor antibody
US11390656B2 (en) * 2015-08-04 2022-07-19 New York University Progranulin (PGRN) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
RU2634113C1 (ru) * 2016-11-18 2017-10-24 Государственное бюджетное учреждение "Академия наук Республики Саха (Якутия)" (ГБУ АН РС(Я)) Способ фиксации головного мозга ископаемого позднеплейстоценового млекопитающего
MX2019007719A (es) 2016-12-26 2019-09-09 Japan Chem Res Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefalica.
EP3561058A4 (en) 2016-12-26 2020-07-22 JCR Pharmaceuticals Co., Ltd. FUSION PROTEIN INCLUDING BDNF
JP2021500857A (ja) 2017-10-02 2021-01-14 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 酵素補充療法用酵素を含む融合タンパク質
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
AU2020215263A1 (en) 2019-02-01 2021-09-09 Oxyrane Uk Ltd Glucocerebrosidase polypeptides
RU2723187C1 (ru) * 2019-10-04 2020-06-09 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Генетическая кассета, содержащая кодон-оптимизированные нуклеотидные последовательности генов HEXA и HEXВ, и фармацевтическая композиция для лечения болезни Тея-Сакса

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
AU7676894A (en) 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
WO1995029993A1 (en) 1994-04-28 1995-11-09 The University Of Michigan Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
WO1996033280A1 (en) 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
DK1445322T4 (da) 1995-06-15 2012-09-03 Crucell Holland Bv Pakningssystemer for humant rekombinant adenovirus til anvendelse ved genterapi
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
NZ330553A (en) 1996-01-05 2001-04-27 Genetic Therapy Inc Recombinase-mediated generation of adenoviral vectors where all adenoviral genes of all regions E1 to E4 and L1 to L5 of the adenoviral genome are eliminated
US5735814A (en) * 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
ES2581828T3 (es) * 1996-09-13 2016-09-07 Shire Human Genetic Therapies, Inc. Proceso de purificación de alfa-galactosidasa A
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en) 1998-05-01 1999-11-11 Genzyme Corporation Partially deleted adenoviral vectors
US6702945B2 (en) 2000-12-28 2004-03-09 Exxonmobil Research And Engineering Company Ionic membranes for organic sulfur separation from liquid hydrocarbon solutions
US6689756B2 (en) 2001-03-02 2004-02-10 Integra Lifesciences Corporation Treatment of neurological disease
US20030163181A1 (en) 2001-12-07 2003-08-28 Neuron Therapeutics, Inc. Protection of neurological tissue by direct CNS perfusion cooling
WO2004047768A2 (en) 2002-11-26 2004-06-10 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
JP2006519609A (ja) 2003-03-12 2006-08-31 サマリタン・ファーマシューティカルズ・インコーポレイテッド 神経疾患擬態動物モデル
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2005072049A2 (en) 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005095955A1 (en) 2004-03-31 2005-10-13 Children, Youth And Women's Health Service Screening for lysosomal storage disease status
WO2005099748A1 (de) * 2004-04-13 2005-10-27 Cilian Ag Rekombinante lysosomale enzyme mit ciliaten-typischem glykosylierungsmuster für die therapie
WO2006007560A2 (en) * 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
AR059088A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
LT1988823T (lt) 2006-02-09 2018-12-10 Genzyme Corporation Lėtas intraventrikuliarinis pateikimas
WO2008154198A1 (en) 2007-06-06 2008-12-18 Genzyme Corporation Gene therapy for lysosomal storage diseases

Also Published As

Publication number Publication date
RU2529830C2 (ru) 2014-09-27
SI1984018T1 (sl) 2014-11-28
TR201903855T4 (tr) 2019-04-22
JP2009525963A (ja) 2009-07-16
ES2526710T3 (es) 2015-01-14
RU2008134120A (ru) 2010-02-27
EP1984018A4 (en) 2010-07-21
RU2018129747A (ru) 2020-02-19
PL1984018T3 (pl) 2015-04-30
US8926967B2 (en) 2015-01-06
US20210228692A1 (en) 2021-07-29
AR059089A1 (es) 2008-03-12
RU2014129319A (ru) 2016-02-10
CA2636991A1 (en) 2007-07-26
MX349749B (es) 2017-08-10
HUE041840T2 (hu) 2019-05-28
ES2716206T3 (es) 2019-06-11
AR109170A2 (es) 2018-11-07
US20090130079A1 (en) 2009-05-21
US20150313970A1 (en) 2015-11-05
EP1984018A2 (en) 2008-10-29
DK2666476T3 (en) 2019-04-08
LT2666476T (lt) 2019-04-10
BRPI0706699A2 (pt) 2011-04-05
EP3517124A1 (en) 2019-07-31
IL192740A (en) 2017-11-30
EP2666476A1 (en) 2013-11-27
PT2666476T (pt) 2019-03-28
RU2665381C2 (ru) 2018-08-29
WO2007084737A3 (en) 2008-10-23
PT1984018E (pt) 2014-10-22
CN101431960A (zh) 2009-05-13
EP2666476B1 (en) 2018-12-19
CA2966155A1 (en) 2007-07-26
WO2007084737A2 (en) 2007-07-26
CA2636991C (en) 2017-07-04
US10080783B2 (en) 2018-09-25
DK1984018T3 (da) 2014-11-03
EP1984018B1 (en) 2014-10-01
IL250937A0 (en) 2017-04-30
JP5681345B2 (ja) 2015-03-04
IL192740A0 (en) 2009-02-11
SI2666476T1 (sl) 2019-04-30
US20190083582A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
PL2666476T3 (pl) Dokomorowe dostarczanie enzymu dla lizosomalnych chorób spichrzeniowych
IL266734B (en) Gene therapy for lysosomal storage diseases
EP2056918A4 (en) CATHETER FOR CELL RELEASE
EP2047372A4 (en) PUSHED MEDIA CONTENT DELIVERY
IL198893A0 (en) Lipase variants for pharmaceutical use
PT1988823T (pt) Administração intraventricular lenta
EP2008529A4 (en) BONBON CONTAINING AN ENZYME
EP2106262A4 (en) NEW ALLERGENS OF THE KALLIKREINE OF THE PROSTATE
ZA200809620B (en) Enzymes for degrading herbicides
ZA201000215B (en) Sequential enzyme delivery system
GB2467284B (en) Sulfatase enzymes
GB0600862D0 (en) Enzyme
EP2045325A4 (en) ENZYME OF PHOSPHORYLATION OF A MEDICAMENT
GB0618149D0 (en) Enzyme II
GB0623222D0 (en) Perillyl alcohol modifying enzymes
GB0616952D0 (en) Delivery
GB0704778D0 (en) Chitinase Enzymes
AU2006900619A0 (en) Improved tank
AU2006904253A0 (en) Fluid Delivery
GB0616772D0 (en) Delivery/box
AU2006903768A0 (en) Tank
AU2006904781A0 (en) Tank
PL379039A1 (pl) Rozdrabniacz zwłaszcza do słomy